CLAL BIOTECHNOLOGY (Israel) Performance

<div class='logoBackup' style='background:#FF9E01;color: white;font-size:3em;;'>CLA</div>
The firm owns Beta (Systematic Risk) of 0.0 which signifies that the returns on MARKET and CLAL BIOTECHNOLOGY are completely uncorrelated. Although it is extremely important to respect CLAL BIOTECHNOLOGY existing price patterns, it is better to be realistic regarding the information on equity price patterns. The philosophy in foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By analyzing CLAL BIOTECHNOLOGY technical indicators you can right now evaluate if the expected return of 0.0% will be sustainable into the future. CLAL BIOTECHNOLOGY at this time owns a risk of 0.0%. Please confirm CLAL BIOTECHNOLOGY Jensen Alpha, Semi Variance and the relationship between Standard Deviation and Value At Risk to decide if CLAL BIOTECHNOLOGY will be following its current price history.
00

Risk-Adjusted Performance

Over the last 30 days CLAL BIOTECHNOLOGY has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, CLAL BIOTECHNOLOGY is not utilizing all of its potentials. The current stock price disturbance, may contribute to short term losses for the investors.
Quick Ratio3.52
Fifty Two Week Low178.20
Target High Price30.00
Fifty Two Week High240.00
Target Low Price30.00
Horizon     30 Days    Login   to change

CLAL BIOTECHNOLOGY Relative Risk vs. Return Landscape

If you would invest (100.00)  in CLAL BIOTECHNOLOGY on December 20, 2019 and sell it today you would earn a total of  100.00  from holding CLAL BIOTECHNOLOGY or generate -100.0% return on investment over 30 days. CLAL BIOTECHNOLOGY is producing return of less than zero assuming 0.0% volatility of returns over the 30 days investment horizon. Simply put, 0% of all equities have less volatile historical return distribution than CLAL BIOTECHNOLOGY and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
    
  Risk (%) 

CLAL BIOTECHNOLOGY Market Risk Analysis

Sharpe Ratio = 0.0
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
CBI
Based on monthly moving average CLAL BIOTECHNOLOGY is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CLAL BIOTECHNOLOGY by adding it to a well-diversified portfolio.

CLAL BIOTECHNOLOGY Alerts

Equity Alerts and Improvement Suggestions

CLAL BIOTECHNOLOGY is not yet fully synchronised with the market data
CLAL BIOTECHNOLOGY has some characteristics of a very speculative penny stock
CLAL BIOTECHNOLOGY has high likelihood to experience some financial distress in the next 2 years
The company reported revenue of 12.29 M. Net Loss for the year was (31.57 M) with loss before overhead, payroll, taxes, and interest of (4.83 M).
CLAL BIOTECH has accumulated about 94.71 M in cash with (69.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59.
See also Trending Equities. Please also try Balance Of Power module to check stock momentum by analyzing balance of power indicator and other technical ratios.
Company logos by clearbit